interferon-β
Type I Interferon’s Dual Effect on Immunity
Reduced Inflammation but Increased Susceptibility to Candidiasis
Interferon Beta-1b for the Treatment of Pediatric Multiple Sclerosis
Two-Year Study Results
Efficacy and Safety of Type I and III Interferons in the Treatment of COVID-19
Systematic review and meta-analysis
How Helicobacter Interferes with Probiotics to Stimulate The Synthesis of IFN-β
The bacterium produces a unique toxin VacA
How to Choose the Right Probiotic
An experiment on 43 strains shows that probiotics stimulate or suppress interferon synthesis depending on the type
A Delicate Balance of Type I Interferon Defeats Fungus
Impaired interferon response contributes to inflammation and severe fungal infections
Omicron and Delta are The Most Interferon-Resistant COVID-19 Strains
IFN-alpha8, IFN-beta, and IFN-omega coronavirus are most effectively suppressed
Interferon-beta Suppresses Monkeypox
Laboratory study of monkeypox prevention and treatment
Chronic Stress Increases Interferon-Beta Levels and Causes Neuroinflammation
Neuroinflammation and Behavioral Disorders Depend on Complement C3 Protein
Late Treatment of COVID-19 Patients with Interferon-Beta Increases Mortality
A double-blind, randomized, placebo-controlled study
Inhaled interferon-beta is effective and safe in treating SARS-CoV-2
British randomized, double-blind, placebo-controlled trial, Phase 2
Inhalation of interferon β-1a reduces mortality in COVID-19 and accelerates recovery
The results of the phase 2 study of the effectiveness of interferon β-1a inhalation in coronavirus infection have been published
Dexamethasone – a promising treatment for COVID-19
Dexamethasone reduces mortality among seriously ill patients with coronavirus
Microbiota protects against the flu
Tonic interferon signals in the stroma of the lungs are controlled by the microbiota and increase resistance to flu
Treating COVID-19 with interfron-beta-1a twice reduces mortality
Subcutaneous administration of interferon three times a week increases the frequency of discharge on day 14 from 44% to 67%
Severe COVID-19 is associated with SARS-CoV-2 ability to suppress interferon production
Interferon beta is not detecting in the body of infected people. The level of interferon-alpha decreases with increasing severity of the disease
Type I interferons as a perspective treatment for COVID-19
Efficacy and safety of IFN-I in treating the new coronavirus